Technical Analysis for SESN - Sesen Bio, Inc.

Grade Last Price % Change Price Change
grade D 0.88 -3.19% -0.03
SESN closed down 3.19 percent on Friday, March 22, 2019, on 81 percent of normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Up Down
See historical SESN trend table...

Date Alert Name Type % Chg
Mar 22 Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.00%
Mar 22 Down 3 Days in a Row Weakness 0.00%
Mar 21 Fell Below 20 DMA Bearish -3.19%
Mar 21 MACD Bearish Signal Line Cross Bearish -3.19%
Mar 20 Narrow Range Bar Range Contraction -8.68%
Mar 19 Narrow Range Bar Range Contraction -10.20%
Mar 19 NR7 Range Contraction -10.20%
Mar 19 NR7-2 Range Contraction -10.20%
Mar 19 Wide Bands Range Expansion -10.20%
Mar 18 Non-ADX 1,2,3,4 Bullish Bullish Swing Setup -8.24%

Older signals for SESN ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Sesen Bio, Inc., a late-stage clinical company, develops next-generation antibody-drug conjugate therapies for patients with cancer. It develops its products based on its Targeted Protein Therapeutics (TPTs) platform. The company's lead product candidate is Vicinium, a fusion protein that is in Phase III clinical trial for the treatment of high-grade non-muscle invasive bladder cancer. It also develops Vicinium in combination with Durvalumab, which is in Phase I clinical trial for the treatment of high-grade non-muscle invasive bladder cancer; and Vicinium in combination with AstraZeneca's checkpoint inhibitor for the treatment of squamous cell carcinoma of the head and neck. In addition, the company is developing systemically-administered TPTs, including VB6-845d for the treatment of solid tumors. The company was formerly known as Eleven Biotherapeutics, Inc. and changed its name to Sesen Bio, Inc. in May 2018. Sesen Bio, Inc. was founded in 2008 and is based in Cambridge, Massachusetts.
Medicine Cancer Oncology Solid Tumors Monoclonal Antibodies Astrazeneca Bladder Cancer Its Its Products Squamous Cell Carcinoma
Is SESN a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 2 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 3.5
52 Week Low 0.66
Average Volume 1,427,233
200-Day Moving Average 1.5516
50-Day Moving Average 0.8438
20-Day Moving Average 0.9496
10-Day Moving Average 0.9618
Average True Range 0.068
ADX 21.23
+DI 20.1262
-DI 22.3777
Chandelier Exit (Long, 3 ATRs ) 0.896
Chandelier Exit (Short, 3 ATRs ) 1.004
Upper Bollinger Band 1.0629
Lower Bollinger Band 0.8363
Percent B (%b) 0.19
BandWidth 23.862679
MACD Line 0.0147
MACD Signal Line 0.0228
MACD Histogram -0.008
Fundamentals Value
Market Cap 13.54 Million
Num Shares 15.4 Million
EPS 0.11
Price-to-Earnings (P/E) Ratio 8.00
Price-to-Sales 0.56
Price-to-Book 1.03
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.96
Resistance 3 (R3) 0.96 0.94 0.95
Resistance 2 (R2) 0.94 0.92 0.94 0.94
Resistance 1 (R1) 0.91 0.90 0.90 0.91 0.94
Pivot Point 0.88 0.88 0.88 0.88 0.88
Support 1 (S1) 0.85 0.86 0.84 0.85 0.82
Support 2 (S2) 0.83 0.85 0.83 0.82
Support 3 (S3) 0.80 0.83 0.81
Support 4 (S4) 0.80